Supplementation with high concentrations of the pyridoxine form of
Vitamin B6 competitively inhibits the active Pyridoxal 5' phosphate (P5P) form which actually leads to decreased
vitamin B6 function rather than enhancing it
https://www.sciencedirect.com/science/article/abs/pii/S0887233317301959?via=ihub
Vitamin B6 normally needs Zinc, Magnesium, and Vitamin B2 (flavin mononucleotide (FMN); also known as riboflavin-5’-phosphate) in the conversion to active B6 (P5P). Levels may start to appear high even without supplementation due to non conversion. As zinc absorption is lowered and also becomes less available to utilize under inflammation/infection conditions, conversion to active B6 can become impacted during that time which becomes problematic mainly if inflammation becomes Chronically high for awhile.
The active form of Vitamin B6 (P5P) prevents IL-1β production by inhibiting NLRP3 inflammasome activation and suggest its potential for preventing inflammatory diseases driven by the NLRP3 inflammasome.
https://pubmed.ncbi.nlm.nih.gov/27733681/
The marginal vitamin B6 deficiency appears to relate to an increased risk of inflammation-related diseases, Recent studies have revealed that vitamin B6 treatment increases cardiac levels of imidazole dipeptides (eg, carnosine, anserine, and homocarnosine), histamine, and -aminobutyric acid (GABA)
and suppresses P2X7 receptor-mediated NLRP3 inflammasome. These modulations may implicate possible cardioprotective mechanisms of vitamin B6. These modulations may also be involved in the underlying mechanisms through which vitamin B6 suppresses oxidative stress and inflammation. (the active pyridoxal 5 phosphate (P5P) NOT pyridoxine which lowers active b6)
https://link.springer.com/article/10.1007/s00394-021-02665-2